An internal standard for the quantification of pirfenidone
Related Products
Unlabeled Version(s)
13986Pirfenidone
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Pirfenidone-d5

Item No. 26452

Technical Information
Formal Name
5-methyl-1-(phenyl-2,3,4,5,6-d5)-2(1H)-pyridinone
CAS Number
1020719-62-3
Molecular Formula
C12H6D5NO
Formula Weight
Purity
≥99% deuterated forms (d1-d5)
A solid
Chloroform: solubleMethanol: soluble
SMILES
CC(C=C1)=CN(C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])C1=O
InChi Code
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3/i2D,3D,4D,5D,6D
InChi Key
ISWRGOKTTBVCFA-VIQYUKPQSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Pirfenidone-d5 is intended for use as an internal standard for the quantification of pirfenidone (Item No. 13986) by GC- or LC-MS. Pirfenidone is an orally bioavailable pyridone derivative with antifibrotic, anti-inflammatory, and antioxidant activities.1,2,3,4,5 It inhibits TGF-β1-stimulated increases in collagen type I, fibronectin, and Hsp47 expression in A549 lung cancer cells in a concentration-dependent manner.4 Pirfenidone (300 mg/kg per day) inhibits fibrosis and inhibits increases in collagen content, fibrocyte pool size, and the levels of chemokines CCL2 and CCL12 in lung in a mouse model of pulmonary fibrosis induced by bleomycin (Item No. 13877).2 In a mouse model of non-alcoholic steatohepatitis (NASH), pirfenidone inhibits fibrosis and increases in hepatocyte apoptosis, lobular inflammation, and hepatic expression of the fibrosis-related genes Col1a1, Timp1, Tgfb1, Pdgfb, and Fgf2 when administered at a dose of 280 mg/kg but has no effect on steatosis.1 Pirfenidone also inhibits NADPH-dependent lipid peroxidation in sheep liver microsomes and scavenges hydroxyl radicals (IC50s = ~6 and ~2.5 mM, respectively).3 Formulations containing pirfenidone have been used in the treatment of idiopathic pulmonary fibrosis.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Komiya, C., Tanaka, M., Tsuchiya, K., et alAntifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis. Sci. Rep. 7:44754, (2017).

    2. Inomata, M., Kamio, K., Azuma, A., et alPirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir. Res. 15:16, (2014).

    3. Misra, H.P., and Rabideau, C. Pirfenidone inhibits NADPH-dependent microsomal lipid peroxidation and scavenges hydroxyl radicals. Mol. Cell. Biochem. 204(1-2), 119-126 (2000).

    4. Hisatomi, K., Mukae, H., Sakamoto, N., et alPirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells. BMC Pulm. Med. 12:24, (2012).

    5. Moeller, A., Ask, K., Warburton, D., et alThe bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40(3), 362-382 (2008).